InSphero's new EU subsidiary opens for business
Schlieren, Switzerland, November 25, 2013 - After successfully launching its US office in April this year, InSphero has now opened a European sales office in Germany for its customers within the European Union.
In September 2013, InSphero, a leading Swiss supplier of organotypic, biological, in vitro 3D microtissues for highly predictive drug testing, opened a fully owned EU subsidiary in Waldshut, Germany, just over the border, to better serve its European Union customers. Following the successful launch of the company's US office back in April, the new European branch aims to serve InSphero's growing number of customers from the European Union more effectively and expand its EU business, which has always represented an important target market.
The idea of the subsidiary is to speed up the purchasing process and make it easier for InSphero's customers in the EU. The company's 3D InSight™ microtissues and GravityPLUS™ 3D Cell Culture Kits will now be delivered to customers without customs clearance delays and with lower shipping costs than when microtissues were shipped from the InSphero headquarters in Switzerland.
"Our European customers really appreciate the fact that they are now able to obtain our InSphero 3D cell culture products for their assays within twenty-four hours, without them getting held up at customs," explains Björn Niggemann, Head of Operations at InSphero, who is also responsible for export and distribution and since September has successfully been processing shipments through this new channel with his team. "And apart from anything else, customers also stand to benefit from 15-20% lower shipping costs."
With all these advantages for the customer, the new office is bound to boost sales this side of the Atlantic.
